Trial Outcomes & Findings for Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders (NCT NCT04090879)
NCT ID: NCT04090879
Last Updated: 2025-04-01
Results Overview
Cigarettes per day will be assessed for use of cigarettes with different nicotine content.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
326 participants
Primary outcome timeframe
16 weeks
Results posted on
2025-04-01
Participant Flow
Participant milestones
| Measure |
RC 1 Only
Research Cigarettes #1
Participants in this group were randomized to receive normal nicotine content cigarettes (15.8mg/g) only, and e-cigarettes were not available. This condition of the intervention applied to these participants throughout all timepoints of the study
1. Altering the nicotine content of the tobacco research cigarette
2. Altering the availability of e-cigarettes
|
RC 2 Only
Research Cigarettes #2
Participants in this group were randomized to receive reduced nicotine content cigarettes (0.4mg/g) only, and e-cigarettes were not available. This condition of the intervention applied to these participants throughout all timepoints of the study
1. Altering the nicotine content of the tobacco research cigarette
2. Altering the availability of e-cigarettes
|
RC 2 + EC 1
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Participants in this group were randomized to receive reduced nicotine content cigarettes (0.4mg/g) only, and tobacco flavor e-cigarettes only. This condition of the intervention applied to these participants throughout all timepoints of the study
1. Altering the nicotine content of the tobacco research cigarette
2. Altering the availability of e-cigarettes
3. Altering option to personalize the e-liquid in the e-cig condition
|
RC 2 + EC 2
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Participants in this group were randomized to receive reduced nicotine content cigarettes (0.4mg/g) only, and were given availability to a variety of flavors, and thus were able to select preferred flavor. This condition of the intervention applied to these participants throughout all timepoints of the study
1. Altering the nicotine content of the tobacco research cigarette
2. Altering the availability of e-cigarettes
3. Altering option to personalize the e-liquid in the e-cig condition
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
83
|
85
|
74
|
84
|
|
Overall Study
COMPLETED
|
67
|
66
|
57
|
70
|
|
Overall Study
NOT COMPLETED
|
16
|
19
|
17
|
14
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Baseline characteristics by cohort
| Measure |
RC 1 Only
n=83 Participants
Research Cigarettes #1
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 Only
n=85 Participants
Research Cigarettes #2
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 + EC 1
n=74 Participants
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
RC 2 + EC 2
n=84 Participants
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
Total
n=326 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
39.77 years
STANDARD_DEVIATION 10.98 • n=5 Participants
|
39.85 years
STANDARD_DEVIATION 9.28 • n=7 Participants
|
41.51 years
STANDARD_DEVIATION 12.39 • n=5 Participants
|
39.38 years
STANDARD_DEVIATION 10.59 • n=4 Participants
|
40.09 years
STANDARD_DEVIATION 10.79 • n=21 Participants
|
|
Sex: Female, Male
Female
|
65 Participants
n=5 Participants
|
69 Participants
n=7 Participants
|
50 Participants
n=5 Participants
|
59 Participants
n=4 Participants
|
243 Participants
n=21 Participants
|
|
Sex: Female, Male
Male
|
18 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
24 Participants
n=5 Participants
|
25 Participants
n=4 Participants
|
83 Participants
n=21 Participants
|
|
Race/Ethnicity, Customized
Black, non-Latino
|
9 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
33 Participants
n=21 Participants
|
|
Race/Ethnicity, Customized
Latino
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
12 Participants
n=21 Participants
|
|
Race/Ethnicity, Customized
White, non-Latino
|
66 Participants
n=5 Participants
|
68 Participants
n=7 Participants
|
60 Participants
n=5 Participants
|
68 Participants
n=4 Participants
|
262 Participants
n=21 Participants
|
|
Race/Ethnicity, Customized
Non-Latino other or multiracial
|
4 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
19 Participants
n=21 Participants
|
|
Region of Enrollment
United States
|
83 participants
n=5 Participants
|
85 participants
n=7 Participants
|
74 participants
n=5 Participants
|
84 participants
n=4 Participants
|
326 participants
n=21 Participants
|
|
Population
Females with lower educational level
|
20 Participants
n=5 Participants
|
23 Participants
n=7 Participants
|
16 Participants
n=5 Participants
|
21 Participants
n=4 Participants
|
80 Participants
n=21 Participants
|
|
Population
OUD
|
19 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
17 Participants
n=5 Participants
|
19 Participants
n=4 Participants
|
74 Participants
n=21 Participants
|
|
Population
Affective disorders
|
44 Participants
n=5 Participants
|
43 Participants
n=7 Participants
|
41 Participants
n=5 Participants
|
44 Participants
n=4 Participants
|
172 Participants
n=21 Participants
|
|
Educational level
<High school
|
9 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
14 Participants
n=4 Participants
|
30 Participants
n=21 Participants
|
|
Educational level
High school graduate, equivalency, or some college
|
51 Participants
n=5 Participants
|
57 Participants
n=7 Participants
|
46 Participants
n=5 Participants
|
47 Participants
n=4 Participants
|
201 Participants
n=21 Participants
|
|
Educational level
Associate's degree
|
8 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
13 Participants
n=5 Participants
|
11 Participants
n=4 Participants
|
43 Participants
n=21 Participants
|
|
Educational level
≥College graduate
|
15 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
52 Participants
n=21 Participants
|
|
Marital status
Married
|
8 Participants
n=5 Participants
|
15 Participants
n=7 Participants
|
17 Participants
n=5 Participants
|
11 Participants
n=4 Participants
|
51 Participants
n=21 Participants
|
|
Marital status
Never married
|
49 Participants
n=5 Participants
|
47 Participants
n=7 Participants
|
36 Participants
n=5 Participants
|
48 Participants
n=4 Participants
|
180 Participants
n=21 Participants
|
|
Marital status
Divorced, separated, or widowed
|
26 Participants
n=5 Participants
|
23 Participants
n=7 Participants
|
21 Participants
n=5 Participants
|
25 Participants
n=4 Participants
|
95 Participants
n=21 Participants
|
|
Primarily smokes mentholated cigarettes
|
32 Participants
n=5 Participants
|
35 Participants
n=7 Participants
|
31 Participants
n=5 Participants
|
33 Participants
n=4 Participants
|
131 Participants
n=21 Participants
|
|
Cigarettes smoked per day
|
16.42 cigarettes per day
STANDARD_DEVIATION 8.02 • n=5 Participants
|
18.44 cigarettes per day
STANDARD_DEVIATION 9.47 • n=7 Participants
|
17.86 cigarettes per day
STANDARD_DEVIATION 9.11 • n=5 Participants
|
16.90 cigarettes per day
STANDARD_DEVIATION 8.85 • n=4 Participants
|
17.40 cigarettes per day
STANDARD_DEVIATION 8.87 • n=21 Participants
|
|
Urine cotinine level
|
4499.25 ng/mL
STANDARD_DEVIATION 3120.20 • n=5 Participants
|
5235.67 ng/mL
STANDARD_DEVIATION 3251.28 • n=7 Participants
|
5156.57 ng/mL
STANDARD_DEVIATION 4150.44 • n=5 Participants
|
5293.33 ng/mL
STANDARD_DEVIATION 3799.45 • n=4 Participants
|
5043.55 ng/mL
STANDARD_DEVIATION 3680.12 • n=21 Participants
|
|
Breath CO level
|
20.90 ppm
STANDARD_DEVIATION 14.02 • n=5 Participants
|
19.30 ppm
STANDARD_DEVIATION 12.39 • n=7 Participants
|
21.03 ppm
STANDARD_DEVIATION 13.38 • n=5 Participants
|
20.66 ppm
STANDARD_DEVIATION 13.44 • n=4 Participants
|
20.46 ppm
STANDARD_DEVIATION 13.28 • n=21 Participants
|
|
Age started smoking regularly
|
16.61 years
STANDARD_DEVIATION 3.97 • n=5 Participants
|
15.92 years
STANDARD_DEVIATION 3.91 • n=7 Participants
|
16.24 years
STANDARD_DEVIATION 3.84 • n=5 Participants
|
16.79 years
STANDARD_DEVIATION 5.15 • n=4 Participants
|
16.39 years
STANDARD_DEVIATION 4.26 • n=21 Participants
|
|
FTND total score
|
5.12 scores on a scale
STANDARD_DEVIATION 2.24 • n=5 Participants
|
5.31 scores on a scale
STANDARD_DEVIATION 2.20 • n=7 Participants
|
5.26 scores on a scale
STANDARD_DEVIATION 2.31 • n=5 Participants
|
4.70 scores on a scale
STANDARD_DEVIATION 2.07 • n=4 Participants
|
5.09 scores on a scale
STANDARD_DEVIATION 2.21 • n=21 Participants
|
|
Used other tobacco products, past 30 days
|
5 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
23 Participants
n=21 Participants
|
|
Used e-cigarettes, past 30 days
|
13 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
13 Participants
n=4 Participants
|
42 Participants
n=21 Participants
|
PRIMARY outcome
Timeframe: 16 weeksPopulation: Participants who completed week 16 of study
Cigarettes per day will be assessed for use of cigarettes with different nicotine content.
Outcome measures
| Measure |
RC 1 Only
n=67 Participants
Research Cigarettes #1
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 Only
n=66 Participants
Research Cigarettes #2
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 + EC 1
n=57 Participants
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
RC 2 + EC 2
n=70 Participants
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
|---|---|---|---|---|
|
Cigarettes Per Day
|
22.54 cigarettes per day
Standard Error 1.59
|
14.32 cigarettes per day
Standard Error 1.32
|
11.76 cigarettes per day
Standard Error 1.18
|
7.63 cigarettes per day
Standard Error 0.90
|
Adverse Events
RC 1 Only
Serious events: 9 serious events
Other events: 71 other events
Deaths: 0 deaths
RC 2 Only
Serious events: 4 serious events
Other events: 74 other events
Deaths: 0 deaths
RC 2 + EC 1
Serious events: 4 serious events
Other events: 62 other events
Deaths: 1 deaths
RC 2 + EC 2
Serious events: 2 serious events
Other events: 72 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
RC 1 Only
n=83 participants at risk
Research Cigarettes #1
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 Only
n=85 participants at risk
Research Cigarettes #2
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 + EC 1
n=74 participants at risk
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
RC 2 + EC 2
n=84 participants at risk
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
|---|---|---|---|---|
|
Psychiatric disorders
Psychiatric disorders - Other
|
3.6%
3/83 • Number of events 3 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Gastrointestinal disorders
Esophageal perforation
|
1.2%
1/83 • Number of events 1 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
General disorders
Irritability
|
1.2%
1/83 • Number of events 1 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor Pain
|
1.2%
1/83 • Number of events 1 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Pregnancy, puerperium and perinatal conditions
Pregnancy, puerperium, and perinatal conditions
|
1.2%
1/83 • Number of events 1 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Surgical and medical procedures
Surgical and medical procedures - Other
|
1.2%
1/83 • Number of events 1 • 16 weeks
|
1.2%
1/85 • Number of events 1 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Vascular disorders
Hypertension
|
1.2%
1/83 • Number of events 1 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
1.4%
1/74 • Number of events 1 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Cardiac disorders
Chest pain - cardiac
|
0.00%
0/83 • 16 weeks
|
1.2%
1/85 • Number of events 1 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
General disorders
Fever
|
0.00%
0/83 • 16 weeks
|
1.2%
1/85 • Number of events 1 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Renal and urinary disorders
Renal calculi
|
0.00%
0/83 • 16 weeks
|
1.2%
1/85 • Number of events 1 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
General disorders
Death NOS
|
0.00%
0/83 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
1.4%
1/74 • Number of events 1 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Injury, poisoning and procedural complications
Injury, poisoning, and procedural complications
|
0.00%
0/83 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
1.4%
1/74 • Number of events 1 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/83 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
1.4%
1/74 • Number of events 1 • 16 weeks
|
0.00%
0/84 • 16 weeks
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
0.00%
0/83 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
1.2%
1/84 • Number of events 1 • 16 weeks
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/83 • 16 weeks
|
0.00%
0/85 • 16 weeks
|
0.00%
0/74 • 16 weeks
|
1.2%
1/84 • Number of events 1 • 16 weeks
|
Other adverse events
| Measure |
RC 1 Only
n=83 participants at risk
Research Cigarettes #1
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 Only
n=85 participants at risk
Research Cigarettes #2
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
|
RC 2 + EC 1
n=74 participants at risk
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
RC 2 + EC 2
n=84 participants at risk
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g): 1) Altering the nicotine content of the tobacco research cigarette
E-Cigarettes: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
|
|---|---|---|---|---|
|
Psychiatric disorders
OASIS Score Increase
|
38.6%
32/83 • Number of events 51 • 16 weeks
|
36.5%
31/85 • Number of events 43 • 16 weeks
|
41.9%
31/74 • Number of events 42 • 16 weeks
|
36.9%
31/84 • Number of events 40 • 16 weeks
|
|
Psychiatric disorders
BDI Category Increase
|
34.9%
29/83 • Number of events 51 • 16 weeks
|
34.1%
29/85 • Number of events 40 • 16 weeks
|
35.1%
26/74 • Number of events 34 • 16 weeks
|
29.8%
25/84 • Number of events 41 • 16 weeks
|
|
Psychiatric disorders
Psychiatric disorders
|
32.5%
27/83 • Number of events 53 • 16 weeks
|
32.9%
28/85 • Number of events 43 • 16 weeks
|
25.7%
19/74 • Number of events 27 • 16 weeks
|
28.6%
24/84 • Number of events 37 • 16 weeks
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders
|
27.7%
23/83 • Number of events 38 • 16 weeks
|
31.8%
27/85 • Number of events 44 • 16 weeks
|
24.3%
18/74 • Number of events 40 • 16 weeks
|
21.4%
18/84 • Number of events 35 • 16 weeks
|
|
General disorders
General disorders and administration
|
21.7%
18/83 • Number of events 25 • 16 weeks
|
28.2%
24/85 • Number of events 27 • 16 weeks
|
21.6%
16/74 • Number of events 20 • 16 weeks
|
26.2%
22/84 • Number of events 27 • 16 weeks
|
|
Infections and infestations
Infections and infestations
|
19.3%
16/83 • Number of events 17 • 16 weeks
|
27.1%
23/85 • Number of events 24 • 16 weeks
|
10.8%
8/74 • Number of events 11 • 16 weeks
|
11.9%
10/84 • Number of events 13 • 16 weeks
|
|
Nervous system disorders
Nervous system disorders
|
8.4%
7/83 • Number of events 8 • 16 weeks
|
21.2%
18/85 • Number of events 23 • 16 weeks
|
20.3%
15/74 • Number of events 19 • 16 weeks
|
11.9%
10/84 • Number of events 11 • 16 weeks
|
|
Gastrointestinal disorders
Gastrointestinal disorders
|
10.8%
9/83 • Number of events 14 • 16 weeks
|
20.0%
17/85 • Number of events 25 • 16 weeks
|
18.9%
14/74 • Number of events 20 • 16 weeks
|
20.2%
17/84 • Number of events 23 • 16 weeks
|
|
Vascular disorders
Vascular disorders
|
12.0%
10/83 • Number of events 13 • 16 weeks
|
15.3%
13/85 • Number of events 15 • 16 weeks
|
10.8%
8/74 • Number of events 10 • 16 weeks
|
19.0%
16/84 • Number of events 30 • 16 weeks
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal and connective tissue disorders
|
13.3%
11/83 • Number of events 14 • 16 weeks
|
18.8%
16/85 • Number of events 16 • 16 weeks
|
9.5%
7/74 • Number of events 7 • 16 weeks
|
14.3%
12/84 • Number of events 12 • 16 weeks
|
|
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications
|
7.2%
6/83 • Number of events 7 • 16 weeks
|
4.7%
4/85 • Number of events 7 • 16 weeks
|
5.4%
4/74 • Number of events 4 • 16 weeks
|
6.0%
5/84 • Number of events 8 • 16 weeks
|
|
Surgical and medical procedures
Surgical and medical procedures
|
2.4%
2/83 • Number of events 2 • 16 weeks
|
3.5%
3/85 • Number of events 3 • 16 weeks
|
6.8%
5/74 • Number of events 5 • 16 weeks
|
4.8%
4/84 • Number of events 4 • 16 weeks
|
|
Cardiac disorders
Cardiac disorders
|
4.8%
4/83 • Number of events 6 • 16 weeks
|
2.4%
2/85 • Number of events 4 • 16 weeks
|
4.1%
3/74 • Number of events 4 • 16 weeks
|
6.0%
5/84 • Number of events 5 • 16 weeks
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place